Would you like to participate ask a question join the surfers in our next episode?

S2 E5.1 After the FDA Webcast: Beginning and Ending Perceptions

The Surfers and guests Manal Abdelmalek, Naim Alkhouri, and Akero Therapeutics Chief Development Officer Kitty Yale share high-level perspectives on the FDA Webcast, both before and after the group's detailed conversation

The panel shared overall impressions and key takeaways from the FDA webcast on NASH Drug Development, both before and after the detailed discussion. Key issues included the agency’s continued reliance on histology coupled with a willingness to accept digital pathology results, the importance of risk: benefit ratio in drug evaluation, the importance of a composite fibrosis+steatosis endpoint, and new approaches to clinical trials for cirrhosis.

Request Transcript of This Episode
Request Transcript
First
Last

NASH & Diabetes Podcast and NASH Tsunami Podcast